These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2121494)

  • 41. Effect of long-term treatment with somatostatin analogue (SMS 201-995) on pituitary tumor shrinkage in acromegaly--report of two cases.
    Mukada K; Uozumi T; Takechi A; Arita K; Yano T; Hirohata T; Onda J; Ohta M
    Neurol Med Chir (Tokyo); 1992 Apr; 32(4):215-9. PubMed ID: 1378566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of pancreatic secretion under long-term octreotide treatment in humans.
    Friess H; Bordihn K; Ebert M; Malfertheiner P; Kemmer T; Dennler HJ; Büchler MW
    Digestion; 1994; 55 Suppl 1():10-5. PubMed ID: 8132133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
    Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.
    Sassolas G; Harris AG; James-Deidier A
    J Clin Endocrinol Metab; 1990 Aug; 71(2):391-7. PubMed ID: 2199479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
    McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of octreotide, a long-acting somatostatin analogue, on plasma amino acid uptake by the pancreas.
    Gullo L; Pezzilli R; Ancona D; Labate AM; Barbara L
    Pancreas; 1991 Nov; 6(6):668-72. PubMed ID: 1780327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegaly.
    van Liessum PA; Swinkels LM; Pieters GF; Ross AA; Smals AG; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):309-12. PubMed ID: 2183534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
    Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
    J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of SMS 201-995 on exocrine pancreatic secretion in a patient with external pancreatic fistula.
    Ohta T; Nagakawa T; Mori K; Kanno M; Kayahara M; Ueno K; Miyazaki I
    Int J Pancreatol; 1992 Jun; 11(3):185-9. PubMed ID: 1517658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
    Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
    Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
    J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
    Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term effect of octreotide in acromegaly on insulin resistance.
    Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
    Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The BT-PABA/PAS test in tropical diabetes.
    Gagee P; Pemberton P; Lobley R; Chaloner C; Snehalatha C; Mohan V; Braganza JM
    Clin Chim Acta; 1992 Nov; 212(3):103-11. PubMed ID: 1477973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholecystokinin in the regulation of gastric acid and endocrine pancreatic secretion in humans.
    Konturek JW; Stoll R; Gutwinska-Konturek M; Konturek SJ; Domschke W
    Scand J Gastroenterol; 1993 May; 28(5):401-7. PubMed ID: 8511500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.